A 2026 scoping review by Kremen et al. (UCLA Health) screened 565 studies across six widely used unapproved peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu — and found the overwhelming majority of evidence is preclinical. Human data are sparse, methodologically weak, and insufficient to establish efficacy for any of the six compounds in any indication.
What Did the 2026 Scoping Review of 565 Studies Actually Find?
The Kremen et al. scoping review covered studies from 1993 to 2024 and identified 565 studies across the six peptides. The vast majority were rodent in vivo or in vitro cell culture experiments. Human interventional data were limited to a small number of low-quality studies — predominantly unblinded, uncontrolled, or too underpowered to support efficacy conclusions.
The review was conducted by orthopaedic researchers at UCLA Health and published in the American Journal of Sports Medicine (Mayfield CK et al., AJSM 2026, PMID 41476424). Its scope encompassed all six compounds simultaneously. The authors concluded that BPC-157 showed the most preclinical activity in tendon and muscle repair, but that these findings remain unvalidated in human trials.
The review's methodology followed PRISMA scoping review guidelines, requiring peer-reviewed publication and direct evaluation of at least one of the six named compounds. Conference abstracts and case reports were excluded from the primary analysis. The resulting evidence map confirmed a structural pattern in which mechanistic and animal-model data are abundant, while human interventional data are nearly absent across all six compounds.
A parallel netnographic analysis by Turnock and Hearne (2025, Performance Enhancement and Health) documented that UK-based users rely primarily on online forum pharmacology rather than clinical evidence. The Turnock study confirmed widespread unregulated use in the absence of human trial data. This gap between community-level adoption and the scientific evidence base is a recurring theme across all six compounds.
What Human Evidence Exists Specifically for BPC-157?
BPC-157 has no completed randomised controlled trial in any human indication as of mid-2026. A Phase 2 RCT in grade II hamstring strain (NCT07437547) is currently recruiting. The preclinical record across tendon, muscle, gut, and neurological models is extensive — over 30 years of rodent data — but none of it has been validated in a published human interventional study.
The Vasireddi et al. systematic review (2025, Sports Health, PMC12313605) surveyed 36 BPC-157 studies published between 1993 and 2024 and found zero human interventional trials. Every included study was a rodent in vivo model or an in vitro cell culture experiment. The mechanistic picture is coherent — angiogenesis via VEGFR2, fibroblast migration via FAK-paxillin, collagen synthesis via growth hormone receptor upregulation — but clinical translation has not occurred in any published dataset.
The July 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) review of BPC-157 cited three specific biopharmaceutical deficiencies including injectable immunogenicity risk from uncharacterised impurity profiles, an intravenous half-life under 16 minutes in animal models, and a complete absence of human safety data. The PCAC voted 8 to 6 to recommend BPC-157 for the 503A Bulks List despite staff's negative briefing. This was a non-binding advisory outcome that does not alter the underlying evidence deficit.
The McGuire et al. narrative review (2025, PMC12446177) flagged BPC-157's VEGFR2-mediated angiogenic activity as a theoretical oncogenic concern. Sustained VEGF pathway upregulation in the context of occult malignancy has not been evaluated in any human safety study. This risk is unquantified and not confirmed, but it is also not excluded by any existing human dataset.
What Human Evidence Exists for TB-500?
TB-500 — a synthetic 17-amino-acid fragment of Thymosin Beta-4 (Tβ4) — has no published human clinical trial data. Human evidence for the parent molecule Tβ4 exists only in ophthalmic indications via topical administration and in one Phase 2 intravenous safety study in acute myocardial infarction. None of these datasets transfer to injectable TB-500 in musculoskeletal indications.
The structural distinction between TB-500 and full-length Tβ4 is pharmacologically material. TB-500 retains the LKKTET actin-sequestering hexapeptide motif but lacks the N-terminal Ac-SDKP tetrapeptide that independently mediates Tβ4's anti-inflammatory and anti-fibrotic effects. The two molecules are not pharmacologically interchangeable, and evidence generated for Tβ4 cannot be extrapolated to TB-500 without pharmacokinetic and pharmacodynamic bridging data that do not currently exist.
RegeneRx Biopharmaceuticals conducted Phase 2 trials of full-length Tβ4 (RGN-259) in dry eye disease and neurotrophic keratitis. Published results demonstrated safety and tolerability via topical ophthalmic administration, with mixed efficacy signals on primary endpoints. A separate Phase 2 trial of intravenous Tβ4 (RGN-352) in acute myocardial infarction showed acceptable tolerability but was not powered for efficacy.
A 2026 scoping review in Applied Sciences by McGuire et al. confirmed that human evidence for TB-500 specifically was limited to a single included study. Human evidence for Tβ4 was concentrated in ocular and wound/skin settings. The review characterised the preclinical evidence base as robust and mechanistically coherent while explicitly noting that direct TB-500 human data are absent.
What Human Evidence Exists for CJC-1295?
CJC-1295 is the compound among the six with the most substantive human pharmacological data. Two Phase 1/2 trials in healthy adults demonstrated dose-dependent GH and IGF-1 elevation lasting 6 to 11 days after a single injection. However, no human study has evaluated CJC-1295 against a clinical endpoint such as body composition, bone density, or recovery time.
Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism, PMID 16352683) enrolled 64 healthy adults in a randomised, placebo-controlled, dose-escalation study. Subcutaneous CJC-1295 produced between two and tenfold increases in plasma GH sustained for six or more days. IGF-1 elevations of between one and a half and threefold persisted for 9 to 11 days, and the compound was well-tolerated at all doses tested.
This remains the primary human pharmacological dataset for CJC-1295 and has not been replicated or extended in a published clinical outcomes trial. Ionescu and Frohman (2006, PMID 17018654) confirmed that pulsatile GH secretion persists during continuous CJC-1295 stimulation. Neither study evaluated body composition, functional performance, or any patient-reported outcome.
The hormonal surrogate data are real and reproducible, but they do not constitute evidence of clinical benefit. No Phase 3 trial of CJC-1295 has been conducted or registered. Its development was discontinued by ConjuChem after the Phase 1/2 programme, and its current use is entirely off-label.
What Human Evidence Exists for MK-677?
MK-677 (ibutamoren) has the most extensive human trial dataset among the six compounds. Multiple randomised trials have demonstrated significant GH and IGF-1 elevation, increased fat-free mass, and improved bone mineral density in elderly populations. However, no trial has demonstrated a hard clinical outcome benefit, and the compound carries documented adverse effects including insulin resistance and elevated fasting glucose.
Nass et al. (2008, Annals of Internal Medicine, PMID 18981485) conducted a 12-month randomised, double-blind, placebo-controlled trial in 65 healthy older adults. MK-677 significantly increased fat-free mass and enhanced pulsatile GH secretion. However, fasting blood glucose and insulin resistance both increased in the MK-677 group.
Thigh muscle cross-sectional area did not differ significantly between groups despite the lean mass gain. This dissociation between lean mass increase and functional muscle improvement is mechanistically important. MK-677-driven IGF-1 elevation promotes fluid retention and glycogen storage, which can increase fat-free mass measurements without proportional gains in contractile muscle protein.
Long-term safety concerns for MK-677 centre on sustained IGF-1 elevation. Epidemiological data associate elevated circulating IGF-1 with increased risk of colorectal, prostate, and breast cancer, though causality has not been established in interventional studies. The FDA has flagged MK-677 as a compound of concern given its GH-axis activity and the absence of an approved indication.
What Human Evidence Exists for Ipamorelin?
Ipamorelin has one published human pharmacological study demonstrating GH secretion at multiple doses in 40 healthy volunteers (Raun et al., 1998). No completed human trial has evaluated ipamorelin against any clinical endpoint. The compound's human evidence base is limited to a single early-phase pharmacodynamic characterisation study from nearly three decades ago.
The Raun et al. (1998, European Journal of Endocrinology) study established that ipamorelin is a selective GHS-R1a agonist that stimulates GH release without significantly elevating ACTH, cortisol, or prolactin. This selectivity profile distinguishes it from earlier GHRPs such as GHRP-6. The study measured GH secretion as its primary endpoint, not any downstream clinical outcome.
No Phase 2 or Phase 3 trial for ipamorelin has been published or registered on ClinicalTrials.gov in any indication. The compound was investigated by Novo Nordisk in the late 1990s and early 2000s for postoperative ileus, but those trials were discontinued and results were not published in peer-reviewed literature.
The Dominikowski et al. review in Frontiers in Endocrinology (2026) characterised ipamorelin as part of the emerging landscape of performance-enhancing peptides. Its human evidence base remains limited to the single 1998 pharmacodynamic study. The absence of clinical outcomes data was identified as the defining limitation of ipamorelin's evidence profile.
What Human Evidence Exists for GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper) has small controlled trials demonstrating improvements in skin collagen density and dermal thickness when applied topically. Injectable GHK-Cu has no human clinical trial data of any kind. The topical evidence, while real, does not transfer to systemic injection use — a route with no published human pharmacokinetic characterisation.
Pickart et al. (2018, Biomolecules, PMC6073405) reviewed the GHK-Cu clinical literature and identified a series of small controlled trials showing improvements in skin aging markers with topical application. These trials were conducted primarily in cosmetic dermatology contexts with sample sizes of 20 to 60 participants and short follow-up periods. They represent the strongest human evidence for GHK-Cu but are limited to topical delivery and aesthetic endpoints.
The mechanistic basis for GHK-Cu's biological activity is well-characterised at the molecular level. The tripeptide-copper complex upregulates collagen and glycosaminoglycan synthesis, activates matrix metalloproteinases, and modulates gene expression across repair-associated pathways. Pickart's group documented GHK-Cu effects on over 4,000 human genes in transcriptomic analyses, raising questions about specificity at supraphysiological concentrations.
An NPR investigation published in September 2026 documented that injectable GHK-Cu use is expanding in the biohacking community despite the complete absence of human injectable trial data. The investigation noted that the topical cosmetic evidence base is being extrapolated by users to justify systemic injection. This is a route with no published human pharmacokinetic or safety characterisation.
How Should the Evidence Hierarchy for These Six Compounds Be Characterised?
Ranked by human evidence quality: MK-677 leads with multiple RCTs demonstrating pharmacodynamic and body composition effects; CJC-1295 follows with two Phase 1/2 hormonal surrogate trials; GHK-Cu has small topical controlled trials. BPC-157, TB-500, and ipamorelin have minimal to no human interventional data. None of the six has demonstrated a hard clinical outcome benefit in a powered RCT.
The distinction between pharmacodynamic evidence and clinical outcome evidence is critical for interpreting this hierarchy. MK-677 and CJC-1295 have demonstrated that they do what their mechanisms predict — elevate GH and IGF-1 — but elevated GH and IGF-1 are not themselves clinical benefits. The clinical question is whether that hormonal elevation translates into meaningful improvements in muscle function, bone strength, or disease-relevant endpoints. That question remains unanswered for both compounds.
For BPC-157 and TB-500, the evidence gap is more fundamental. There is no human pharmacokinetic data, no dose-exposure characterisation, and no safety signal dataset. The preclinical mechanistic evidence is extensive and internally consistent, but the translational pathway from rodent model to human clinical benefit requires pharmacokinetic bridging that has not been performed.
GHK-Cu occupies a distinct position. It has genuine human evidence, but only for topical delivery in cosmetic indications. The injectable use expanding in the biohacking community is pharmacologically distinct from the topical use that has been studied. Topical application produces local tissue concentrations without meaningful systemic exposure, while injection produces systemic exposure without any characterised dose-response relationship in humans.
What Evidence Would Be Required to Change the Current Verdict for Any of These Compounds?
For BPC-157 and TB-500, the minimum requirement is a completed Phase 2 RCT with a defined clinical endpoint and pharmacokinetic data. For CJC-1295 and ipamorelin, a Phase 2 trial measuring a clinical outcome beyond GH/IGF-1 surrogates is needed. For MK-677, a trial demonstrating functional muscle benefit is required. For GHK-Cu, a Phase 2 injectable trial with safety endpoints is needed.
NCT07437547 — the Phase 2 BPC-157 hamstring strain trial currently recruiting — represents the first step toward addressing the BPC-157 evidence gap. If completed and published, it would provide the first Level 2 evidence for BPC-157 in any musculoskeletal indication, regardless of the direction of the result. The pharmacokinetic data generated by that trial would be independently valuable even if the primary efficacy endpoints are not met.
The regulatory pathway for these compounds in the United States is not closed. The 503A Bulks List framework permits compounding of substances with adequate human safety and efficacy data. The July 2026 PCAC advisory vote in favour of BPC-157 and TB-500 — despite staff's negative recommendation — signals that some committee members view the preclinical evidence as sufficient to justify access pending further study.
The fundamental challenge for all six compounds is the absence of a pharmaceutical sponsor willing to fund the IND-enabling studies, Phase 1 pharmacokinetics, and Phase 2 efficacy trials required for regulatory validation. Without that investment, the evidence gap will persist regardless of the strength of preclinical data or the volume of community-level use. What New Human Safety Data Exist for BPC-157 in Musculoskeletal Recovery and Gut Repair in 2026? Which of the Seven Peptides Reviewed by the FDA's July 2026 Advisory Panel Have Sufficient Human Safety and Efficacy Data to Justify Compounding? What Does the 2026 McGuire Narrative Review Conclude About BPC-157 — Regeneration or Risk for Musculoskeletal Healing?